Comparative Pharmacology
Head-to-head clinical analysis: BRONKOSOL versus POLMON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOSOL versus POLMON.
BRONKOSOL vs POLMON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in severe hepatic impairment requiring dose adjustment.
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Renal excretion of unchanged drug accounts for 40-50% of elimination; biliary/fecal excretion accounts for 50-60%.
Category C
Category C
Bronchodilator
Bronchodilator